FOR IMMEDIATE RELEASE

Tokyo, May 7, 2012

Termination of all the studies of anti-dyslipidemia drug JTT-705 (dalcetrapib), JT’s partner, F. Hoffmann-La Roche Ltd., has announced

Japan Tobacco Inc. (JT) (TSE: 2914) today announced that F. Hoffmann-La Roche Ltd. (Roche) issued a press release on the termination of the development of JTT-705 (dalcetrapib). JT has concluded a licensing agreement for JTT-705 (dalcetrapib) with Roche in October 2004, granting Roche the rights to develop and commercialize the drug worldwide except for Japan, and currently Roche has been conducting several phase 3 clinical trials.

JTT-705 (dalcetrapib) was discovered by JT with the objective of increasing plasma HDL (High Density Lipoprotein), by modulation of CETP (Cholesteryl Ester Transfer Protein) which transfers cholesterol from HDL to LDL (Low Density Lipoprotein).

This is expected to have only a small impact on JT’s consolidated account in this financial year.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Contact: Hideyuki Yamamoto, General Manager
Media and Investor Relations Division
Japan Tobacco Inc.
Tokyo: +81-3-5572-4292
E-mail: jt.media.relations@jt.com

JAPAN TOBACCO INC.
2-1, Tovanouchi 2-chome, Minato-ku
Tokyo 105-8422 JAPAN
Phone:03-3582-3111

###

Japan Tobacco Inc. is a leading international tobacco product company. Its products are sold in over 120 countries and its internationally recognized cigarette brands include Winston, Camel, Mild Seven and Benson & Hedges. With diversified operations, JT is also actively present in pharmaceuticals and foods. The company’s revenue was ¥2.034 trillion (US$24.745 million(*)) in the fiscal year ended March 31, 2012.

*Translated at the rate of ¥82.19 per $1, as of March, 2012